Abstract
The heart is extensively innervated and its performance is tightly controlled by the nervous system. Cardiac innervation density varies in diseased hearts leading to unbalanced neural activation and lethal arrhythmia. Diabetic sensory neuropathy causes silent myocardial ischemia, characterized by loss of pain perception during myocardial ischemia, which is a major cause of sudden cardiac death in diabetes mellitus (DM). Despite its clinical importance, the mechanisms underlying the control and regulation of cardiac innervation remain poorly understood. We found that cardiac innervation is determined by the balance between neural chemoattractants and chemorepellents within the heart. Nerve growth factor (NGF), a potent chemoattractant, is induced by endothelin-1 upregulation during development and is highly expressed in cardiomyocytes. By comparison, Sema3a, a neural chemorepellent, is highly expressed in the subendocardium of early stage embryos, and is suppressed during development. The balance of expression between NGF and Seme3a leads to epicardial-to-endocardial transmural sympathetic innervation patterning. We also found that downregulation of cardiac NGF leads to diabetic neuropathy, and that NGF supplementation rescues silent myocardial ischemia in DM. Cardiac innervation patterning is disrupted in Sema3a-deficient and Sema3aoverexpressing mice, leading to sudden death or lethal arrhythmias. The present review focuses on the regulatory mechanisms underlying cardiac innervation and the critical role of these processes in cardiac performance.
Keywords: Cardiac nerve, nerve growth factor, Sema3a, arrhythmia, silent myocardial ischemia, sudden cardiac death
Related Journals
Related eBooks
Related Articles
-
History, Prevalence and Assessment of Limited Joint Mobility, from Stiff Hand Syndrome to Diabetic Foot Ulcer Prevention: A Narrative Review of the Literature
Current Diabetes Reviews Executive Function and Diabetes Mellitus - A Stone Left Unturned?
Current Diabetes Reviews Gestational Diabetes and the Metabolic Syndrome: Can Obesity and Small, Dense Low Density Lipoproteins be Key Mediators of this Association?
Current Pharmaceutical Biotechnology Incretin Based Therapy in the Management of Steroid Induced Diabetes Mellitus
Current Diabetes Reviews Diabetes Gene Therapy: Potential and Challenges
Current Gene Therapy Inhibitory Effect of Phenolic Extracts of Four Algerian Atlas Saharan Plants on α-Glucosidase Activity
Current Enzyme Inhibition Novel Glitazones with Diverse Peroxisome Proliferator Activated Receptor Modulatory Potential
Current Bioactive Compounds An Interplay between Obesity and Inflammation in Gestational Diabetes Mellitus
Current Pharmaceutical Biotechnology Serum Carotenoids and Risks of Diabetes and Diabetic Retinopathy in a Chinese Population Sample
Current Molecular Medicine Consequences of Type 1 and 2 Diabetes Mellitus on the Cardiovascular Regulation During Exercise: A Brief Review
Current Diabetes Reviews Therapeutical Perspectives of S-Allylcysteine: Effect on diabetes and other disorders in Animal Models
Cardiovascular & Hematological Agents in Medicinal Chemistry Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 2: Calciferol and the Significance of Nutrient Supplements
Inflammation & Allergy - Drug Targets (Discontinued) Quality of Life of Children with Type 1 Diabetes: A Systematic Review
Current Diabetes Reviews Endothelial Nitric Oxide Synthase Gene Therapy for Erectile Dysfunction
Current Pharmaceutical Design Evaluation of Risk Factors Associated with Diabetic Foot Ulcers in Saudi Arabia
Current Diabetes Reviews Calcium Metabolism and Oxidative Stress in Bone Fractures: Role of Antioxidants
Current Drug Metabolism Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design Enhancement of the Pharmacological Efficacy of FGF-21 by Genetic Modification and PEGylation
Current Pharmaceutical Biotechnology Family History and Preclinical Atherosclerosis
Current Hypertension Reviews Insulin Secreted From Genetically Engineered Intestinal Cells Reduces Blood Glucose Levels in Diabetic Mice
Current Gene Therapy